• Explore /
  • Poster
  • / A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

David Johnson Einstein

Beth-Israel Deaconess Medical Center, Boston, MA

David Johnson Einstein , Atish Dipankar Choudhury , Philip James Saylor , Jesse Christopher Patterson , Peter Croucher , Maya Ridinger , Mark G. Erlander , Michael B. Yaffe , Glenn Bubley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03414034

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS219)

DOI

10.1200/JCO.2022.40.6_suppl.TPS219

Abstract #

TPS219

Poster Bd #

R9

Abstract Disclosures

Similar Posters

First Author: David Johnson Einstein

First Author: David Johnson Einstein

First Author: Benedito A. Carneiro

First Author: Daniel J Khalaf